Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials.
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug
(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.
Viking Therapeutics surges after presenting ‘promising’ obesity drug data
Viking Therapeutics (VKTX) presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental
Viking Therapeutics Jumps On Latest Obesity Drug Data
Viking Therapeutics reported promising early results for its experimental obesity pill, with increased weight loss at higher doses. Viking stock jumped early Monday, but came well off premarket highs.
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations. Patients who received the higher dose 100 milligram version of the oral drug,
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Zacks.com on MSN12d
VKTX Beats on Q3 Earnings, Stock Up on Obesity Pipeline Advancements
Viking Therapeutics VKTX reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
SchaeffersResearch.com1d
Biotech Stock Reverses Gains Despite Obesity Pill Buzz
Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...
bovnews11d
The VKTX Stock Mystery: Why Did VKTX Surge Today?
On Thursday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $73.22 which represents a slight increase of $12.83 or 21.25% from the prior close of $60.39. The stock opened ...
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ...
Viking Therapeutics Inc (VKTX) showcases promising clinical advancements and robust cash reserves, despite increased expenses ...
Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Viking Therapeutics VKTX has outperformed the market over the past 5 years by 49.88% on an annualized basis producing an ...
Viking Therapeutics participates in a conference call with JPMorgan
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...